Please assess the completion status of the following clinical trial:

Trial Title: A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of stage IV NSCLC.~* Have progressed during or after platinum-based chemotherapy for advanced disease.~* Have not received prior treatment with docetaxel.~* Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived material.~* Have adequate organ function including hematology, renal, and liver.~* Have good performance score (0-1).~* Have measurable disease per RECIST 1.1.~* Agree to use a reliable medically approved method of birth control.~Exclusion Criteria:~* Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment administered is not known.~* Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.~* Have the presence of unstable central nervous system (CNS) metastasis.~* Have had major surgery (excluding biopsy) \< 28 days of the initial dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abemaciclib (Type: EXPERIMENTAL): 200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- Docetaxel (Type: ACTIVE_COMPARATOR): 75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).